Fam-Trastuzumab Deruxtecan-Nxki

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan.

Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan.

Journal: Oral oncology

Published: August 17, 2026

Rapid and Efficient Antibody-Drug Conjugate Design Using Mechanistic Bottom-Up Modeling from In Vitro to Human.

Rapid and Efficient Antibody-Drug Conjugate Design Using Mechanistic Bottom-Up Modeling from In Vitro to Human.

Journal: Bioconjugate chemistry

Published: June 19, 2026

ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework.

ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework.

Journal: Pharmaceutics

Published: May 31, 2026

In brief: An expanded indication for Enhertu.

In brief: An expanded indication for Enhertu.

Journal: The Medical letter on drugs and therapeutics

Published: May 15, 2026

Recent advances in Camptothecin-derived antibody-drug conjugates.

Recent advances in Camptothecin-derived antibody-drug conjugates.

Journal: Bioorganic & medicinal chemistry

Published: April 28, 2026

HER2 Immunohistochemical Expression and Fluorescent In Situ Hybridization (FISH) Testing in Clear Cell Carcinoma of the Gynecologic Tract.

HER2 Immunohistochemical Expression and Fluorescent In Situ Hybridization (FISH) Testing in Clear Cell Carcinoma of the Gynecologic Tract.

Journal: Applied immunohistochemistry & molecular morphology : AIMM

Published: April 08, 2026

Hospital in-use evaluation of the physical, chemical and affinity stability of the antibody-drug conjugate trastuzumab deruxtecan (Enhertu®).

Hospital in-use evaluation of the physical, chemical and affinity stability of the antibody-drug conjugate trastuzumab deruxtecan (Enhertu®).

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: February 13, 2026

Dual Targeting of EGFR and HER2 by a Bispecific Antibody-Drug Conjugate Demonstrates Broad Antitumor Activity in Multiple Solid Tumors.

Dual Targeting of EGFR and HER2 by a Bispecific Antibody-Drug Conjugate Demonstrates Broad Antitumor Activity in Multiple Solid Tumors.

Journal: Molecular cancer therapeutics

Published: February 11, 2026

Development of a translational murine model for antibody-drug conjugate-induced interstitial lung disease.

Development of a translational murine model for antibody-drug conjugate-induced interstitial lung disease.

Journal: NPJ precision oncology

Published: December 22, 2025

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.

Journal: Scientific reports

Published: December 19, 2025

Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential.

Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential.

Journal: Journal of medicinal chemistry

Published: December 19, 2025

The Use of Fam-Trastuzumab Deruxtecan-nxki in Treating ERBB2 Amplified Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer: A Case Report.

The Use of Fam-Trastuzumab Deruxtecan-nxki in Treating ERBB2 Amplified Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer: A Case Report.

Journal: Case reports in oncological medicine

Published: October 06, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026